Compare BLNK & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | CYPH |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 73.3M |
| IPO Year | 2008 | 2019 |
| Metric | BLNK | CYPH |
|---|---|---|
| Price | $0.46 | $2.63 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.63 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 14.2M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.22 | ★ 103.87 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $126,197,000.00 | $1,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.70 | $408.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.49 |
| 52 Week High | $2.15 | $4.19 |
| Indicator | BLNK | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 32.44 | 46.87 |
| Support Level | N/A | $0.68 |
| Resistance Level | $0.62 | $3.23 |
| Average True Range (ATR) | 0.03 | 0.36 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 2.74 | 5.18 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The Blink's principal line of products and services is its Blink EV charging networks, Blink EV charging equipment, and other EV-related services. The Blink Network is a proprietary, cloud-based system that operates, maintains, and manages Blink charging stations and handles the associated charging data, back-end operations, and payment processing. The Blink Network provides fleets, property owners, managers, parking companies, and state and municipal entities, among other types of commercial customers, with cloud-based services.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.